特発性肺線維症および間質性肺疾患の予測アウトカム登録 (IPF/ILD-PRO)
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) および慢性線維性間質性肺疾患 (Prospective Outcomes with Progressive Phenotype) (IPF-PRO/ILD-PRO) レジストリ
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
調査の概要
状態
詳細な説明
This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Rosalia Blanco
- 電話番号:919-660-0890
- メール:rosalia.blanco@duke.edu
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- 募集
- University of Alabama - Birmingham
-
主任研究者:
- Tejaswini Kulkarni, MD
-
コンタクト:
- Arnissa Hopson
- 電話番号:205-934-1657
- メール:agoggins@uabmc.edu
-
-
Arizona
-
Tucson、Arizona、アメリカ、85721
- 募集
- University of Arizona
-
主任研究者:
- Sally A Suliman, MD
-
コンタクト:
- Daniel Castaneda-Beltran
- 電話番号:602-827-2347
- メール:dcastanedabeltra@arizona.edu
-
-
California
-
Los Angeles、California、アメリカ、90033
- 募集
- University of Southern California
-
コンタクト:
- Lynn Fukusima
- メール:Lynn.Fukushima@med.usc.edu
-
主任研究者:
- Toby Maher, MD
-
Los Angeles、California、アメリカ、90024
- 募集
- University of California - Los Angeles
-
主任研究者:
- John Belperio, MD
-
コンタクト:
- Stephanie Roblero
- 電話番号:310-627-2319
- メール:sroblero@mednet.ucla.edu
-
Stanford、California、アメリカ、94305
- 募集
- Stanford University
-
主任研究者:
- Rishi Raj, MD
-
コンタクト:
- Summer Zhu
- 電話番号:650-724-5424
- メール:szhuye@stanford.edu
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- University of Colorado
-
主任研究者:
- Joyce Lee, MD
-
コンタクト:
- Olivia Brohl
- 電話番号:303-724-0641
- メール:Olivia.brohl@cuanschutz.edu
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06520
- 募集
- Yale University
-
主任研究者:
- Mridu Gulati, MD
-
コンタクト:
- Maksym Minasyan
- 電話番号:203-785-4177
- メール:maksym.minasyan@yale.edu
-
-
Florida
-
Gainesville、Florida、アメリカ、32610-3175
- 募集
- University of Florida
-
コンタクト:
- Lisbetty Lugo
- メール:lisbetty.lugo@medicine.ufl.edu
-
主任研究者:
- Diana Gomez Manjarres, MD
-
Tampa、Florida、アメリカ、33606
- 募集
- University of South Florida
-
主任研究者:
- Jose D Herazo-Maya, MD
-
コンタクト:
- Natasha Brown
- メール:nbrown@tgh.org
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University
-
コンタクト:
- Tracy Halabi
- 電話番号:404-712-7458
- メール:tracy.halaby@emory.edu
-
主任研究者:
- Srihari Veeraraghavan, MD
-
Austell、Georgia、アメリカ、30106
- 募集
- Piedmont Healthcare
-
主任研究者:
- Amy Case, MD
-
コンタクト:
- Munachi (Muna) Iwotor
- 電話番号:404-291-9062
- メール:munachi.iwotor@piedmont.org
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- 募集
- University of Chicago
-
主任研究者:
- Mary Strek, MD
-
コンタクト:
- Vanita Patel
- メール:vpatel4@bsd.uchicago.edu
-
Evanston、Illinois、アメリカ、60611
- 募集
- Northwestern University
-
コンタクト:
- Phillip Cooper
- 電話番号:312-503-0406
- メール:p-cooper@northwestern.edu
-
主任研究者:
- Bradford Bemiss, MD
-
Maywood、Illinois、アメリカ、60153
- 募集
- Loyola University Health System
-
主任研究者:
- Daniel Dilling, MD
-
コンタクト:
- Sloan White
- メール:swhite29@luc.edu
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- 終了しました
- University of Kansas
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- 募集
- University of Kentucky
-
主任研究者:
- Girish Nair, MD
-
コンタクト:
- Kai Su
- 電話番号:859-257-4501
- メール:kai.su@uky.edu
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70112
- 募集
- Tulane University
-
主任研究者:
- Joe Lasky, MD
-
コンタクト:
- Sandy Ditta
- 電話番号:504-988-4040
- メール:sditta@tulane.edu
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 積極的、募集していない
- University of Michigan
-
Detroit、Michigan、アメリカ、48202
- 募集
- Henry Ford Health
-
コンタクト:
- Deepti Naidu
- 電話番号:313-916-8732
- メール:dnaidu1@HFHS.ORG
-
主任研究者:
- Asif Abdul Hameed, MD
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- 募集
- University of Minnesota
-
コンタクト:
- Mandi DeGrote
- 電話番号:612-626-7609
- メール:carl1032@umn.edu
-
主任研究者:
- Hyum Kim, MD
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- 募集
- University of Mississippi Medical Center
-
主任研究者:
- Kimberly Dobbs, MD
-
コンタクト:
- Leadeashia Brackett
- 電話番号:601-496-7814
- メール:lbrackett@umc.edu
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University
-
主任研究者:
- Tonya Russell, MD
-
コンタクト:
- Mona Noroozi
- 電話番号:314-362-3705
- メール:mnoroozi@wustl.edu
-
-
New York
-
New York、New York、アメリカ、10065
- 募集
- Weill Medical College of Cornell University
-
主任研究者:
- Kerri Aronson, MD
-
コンタクト:
- Alicia Morris
- 電話番号:646-692-2741
- メール:ajm2017@med.cornell.edu
-
New York、New York、アメリカ、10016
- 積極的、募集していない
- NYU Medical Center
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27514
- 募集
- UNC Chapel Hill
-
主任研究者:
- Jason Lobo, MD
-
コンタクト:
- Jackson Pettee
- メール:Jackson_pettee@med.unc.edu
-
Durham、North Carolina、アメリカ、27705
- 募集
- Duke University
-
主任研究者:
- Lake Morrison, MD
-
コンタクト:
- Lauren Gray
- 電話番号:919-684-7317
- メール:lauren.gray@duke.edu
-
Greensboro、North Carolina、アメリカ、27403
- 募集
- Pulmonix LLC
-
主任研究者:
- Murali Ramaswamy, MD
-
コンタクト:
- Mei Zheng
- 電話番号:336-522-8870
- メール:mei.zheng@pulmonix.com
-
Wilmington、North Carolina、アメリカ、28401
- 終了しました
- PMG Research
-
Winston-Salem、North Carolina、アメリカ、27157
- 募集
- Wake Forest Baptist Health
-
コンタクト:
- Bob Hmieleski
- 電話番号:336-713-8550
- メール:bhmieles@wakehealth.edu
-
主任研究者:
- Andrew Namen, MD
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45267
- 積極的、募集していない
- University of Cincinnati Medical Center
-
Cleveland、Ohio、アメリカ、44195
- 募集
- Cleveland Clinic
-
主任研究者:
- Brian Southern, MD
-
コンタクト:
- Ron Wehrmann
- 電話番号:2164450574
- メール:wehrmar@ccf.org
-
Columbus、Ohio、アメリカ、43210
- 募集
- The Ohio State University
-
コンタクト:
- Benjamin Hood
- メール:benjamin.hood2@osumc.edu
-
主任研究者:
- John Odackal
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- 募集
- University of Oklahoma
-
主任研究者:
- Jad Kebbe, MD
-
コンタクト:
- Maria Mason
- 電話番号:405-271-6173
- メール:maria-l-mason@ouhsc.edu
-
-
Oregon
-
Portland、Oregon、アメリカ、97220
- 募集
- Oregon Clinic
-
主任研究者:
- David Hotchkin, MD
-
コンタクト:
- Meg Day
- 電話番号:503-963-3182
- メール:mday@orclinic.com
-
-
Pennsylvania
-
Hershey、Pennsylvania、アメリカ、17033
- 募集
- Penn State College of Medicine - Hershey
-
主任研究者:
- Rebecca Bascom, MD
-
コンタクト:
- Tim Sheehan
- 電話番号:717-531-2925
- メール:tsheehan@pennstatehealth.psu.edu
-
Philadelphia、Pennsylvania、アメリカ、19140
- 募集
- Temple University
-
主任研究者:
- Rachel Criner, MD
-
コンタクト:
- Luis Cardenas-Osorio
- 電話番号:215-707-3311
- メール:Luis.Cardenas-Osorio@tuhs.temple.edu
-
Philadelphia、Pennsylvania、アメリカ、19144
- 募集
- Thomas Jefferson University
-
主任研究者:
- Ross Summer, MD
-
コンタクト:
- Ramya Talluri, BSN, RN
- メール:RamyaPriya.Talluri@jefferson.edu
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- 募集
- Medical University of South Carolina
-
主任研究者:
- Timothy Whelan, MD
-
コンタクト:
- Audra Wiser
- メール:wisera@musc.edu
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- 募集
- Vanderbilt University
-
コンタクト:
- James Del Greco
- 電話番号:615-343-7068
- メール:james.del.greco@vumc.org
-
主任研究者:
- Justin Hewlett, MD
-
-
Texas
-
Dallas、Texas、アメリカ、75235
- 募集
- University of Texas Southwestern
-
主任研究者:
- John Fitzgerald, MD
-
コンタクト:
- Meagan Galvan
- 電話番号:214-645-6489
- メール:Maegan.Galvan@UTSouthwestern.edu
-
Dallas、Texas、アメリカ、75246
- 募集
- Baylor University Medical Center at Dallas
-
主任研究者:
- Yolanda Mageto, MD
-
コンタクト:
- Mary Alayo
- 電話番号:214-820-6276
- メール:Mary.Alayo@BSWHealth.org
-
Houston、Texas、アメリカ、77030
- 募集
- Baylor College of Medicine
-
主任研究者:
- Ivan Rosas, MD
-
コンタクト:
- Maria C Perea
- メール:Maria.Perea@bcm.edu
-
Houston、Texas、アメリカ、77030
- 募集
- Houston Methodist Lung Center
-
主任研究者:
- Zeenat Safdar, MD
-
コンタクト:
- Laura Valecillos Loukidis
- 電話番号:346-238-4637
- メール:lvvalecillosloukidis@houstonmethodist.org
-
Houston、Texas、アメリカ、77030
- 募集
- The University of Texas Health Science Center At Houston
-
主任研究者:
- Rodeo Abrencillo, MD
-
コンタクト:
- Beverly Rios
- 電話番号:713-486-6152
- メール:Beverly.Rios@uth.tmc.edu
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84108
- 募集
- University of Utah
-
コンタクト:
- Adeline Langer
- 電話番号:801-581-5811
- メール:adeline.langer@hsc.utah.edu
-
主任研究者:
- Mary Beth Langer, MD
-
Salt Lake City、Utah、アメリカ、84111
- 募集
- Intermountain Health
-
コンタクト:
- Aisha Skowyra
- 電話番号:801-507-2439
- メール:Aisha.fairclough@imail.org
-
主任研究者:
- Erin Blackstock, MD
-
-
Vermont
-
Colchester、Vermont、アメリカ、05446
- 積極的、募集していない
- University of Vermont Lung Center
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- 積極的、募集していない
- University from Virginia
-
Falls Church、Virginia、アメリカ、22042-3307
- 募集
- Inova Health Care Services
-
コンタクト:
- Taruni Maganti
- 電話番号:703-776-3230
- メール:Taruni.Maganti@inova.org
-
主任研究者:
- Jared Wilkinson, MD
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- 積極的、募集していない
- The Medical College of Wisconsin
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.
説明
Inclusion Criteria:
-
Willing and able to provide informed consent
-
Established a new diagnosis (within 12 months) of IPF by the enrolling center.
-
Age 21 years or older, or
-
Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:
-
Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.
-
Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):
- decline in FVC % predicted (% pred) based on ≥10% relative decline
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
- decline in DLCO % pred based on≥ 10% relative decline
- worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.
-
The relative decline for FVC % predicted is calculated using the formula:
Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.
The relative decline for DLCO % predicted is calculated using the formula:
Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening
Exclusion Criteria:
- Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
- Currently listed for lung transplantation at the time of enrollment
- Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
- For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry |
|
Subjects with a non-IPF ILD diagnosis
Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype |
|
New Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Data on natural history of IPF & non-IPF chronic fibrosing ILD
時間枠:End of Study (3 years after last patient will be enrolled)
|
Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
時間枠:End of Study (3 years after last patient will be enrolled)
|
Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD |
End of Study (3 years after last patient will be enrolled)
|
|
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
時間枠:End of Study (3 years after last patient will be enrolled)
|
Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL). |
End of Study (3 years after last patient will be enrolled)
|
|
Blood samples for future research.
時間枠:End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions. |
End of Study (3 years after last patient will be enrolled)
|
|
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
時間枠:End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal HRCT images for future research |
End of Study (3 years after last patient will be enrolled)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Data on management practices compared to existing guidelines.
時間枠:End of Study (3 years after last patient will be enrolled)
|
Compare disease-specific management practices with existing guidelines. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on center-specific practices on outcomes.
時間枠:End of Study (3 years after last patient will be enrolled)
|
Determine the influence of center-specific practices on patient outcomes. |
End of Study (3 years after last patient will be enrolled)
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Scott Palmer, MD、Duke Clinical Research Institute, Duke University
出版物と役立つリンク
一般刊行物
- Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry investigators. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Ann Am Thorac Soc. 2022 Jun;19(6):981-990. doi: 10.1513/AnnalsATS.202105-589OC.
- Kim HJ, Snyder LD, Neely ML, Hellkamp AS, Hotchkin DL, Morrison LD, Bender S, Leonard TB, Culver DA; IPF-PRO Registry investigators. Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry. Lung. 2022 Feb;200(1):21-29. doi: 10.1007/s00408-021-00506-x. Epub 2022 Jan 7.
- de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2022 Jan 7;23(1):3. doi: 10.1186/s12931-021-01921-7.
- Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4.
- Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, Hartmann N, Palmer SM, Leonard TB; IPF-PRO Registry principal investigators as follows. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020 Nov;17(11):1413-1423. doi: 10.1513/AnnalsATS.201912-880OC.
- Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA; IPF-PRO Registry Investigators. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest. 2020 Jun;157(6):1522-1530. doi: 10.1016/j.chest.2019.12.041. Epub 2020 Jan 29.
- O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB; IPF-PRO Registry investigators. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. Chest. 2020 May;157(5):1188-1198. doi: 10.1016/j.chest.2019.11.042. Epub 2020 Jan 15.
- Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z.
- Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; IPF-PRO Registry investigators. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9.
- O'Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, Conoscenti CS. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res. 2016 Jan 11;3(1):e000108. doi: 10.1136/bmjresp-2015-000108. eCollection 2016.
- Swaminathan AC, Weber JM, Todd JL, Palmer SM, Neely ML, Whelan TP, Kim GHJ, Leonard TB, Goldin J. Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry. Respir Res. 2025 Feb 28;26(1):73. doi: 10.1186/s12931-025-03136-6.
- Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, Palmer SM, Todd JL; IPF-PRO Registry Investigators. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2025 Aug;168(2):415-422. doi: 10.1016/j.chest.2025.02.018. Epub 2025 Feb 26.
- Sack C, Wojdyla DM, MacMurdo MG, Gassett A, Kaufman JD, Raghu G, Redlich CA, Li P, Olson AL, Leonard TB, Todd JL, Neely ML, Snyder LD, Gulati M; IPF-PRO Registry investigators. Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Ann Am Thorac Soc. 2025 Mar;22(3):378-386. doi: 10.1513/AnnalsATS.202404-382OC.
- Wang L, Wu P, Liu Y, Patel DC, Leonard TB, Zhao H. Clustering-aided prediction of outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2024 Oct 23;25(1):383. doi: 10.1186/s12931-024-03015-6.
- Lobo LJ, Liu Y, Li P, Ramaswamy M, Swaminathan AC, Veeraraghavan S, Fan Y, Neely ML, Palmer SM, Olson AL; ILD-PRO Registry investigatorsdagger. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024 Sep 27;24(1):468. doi: 10.1186/s12890-024-03247-8.
- Summer R, Todd JL, Neely ML, Lobo LJ, Namen A, Newby LK, Shafazand S, Suliman S, Hesslinger C, Keller S, Leonard TB, Palmer SM, Ilkayeva O, Muehlbauer MJ, Newgard CB, Roman J. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2024 Jan 25;25(1):58. doi: 10.1186/s12931-023-02644-7.
- Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, Oldham JM, Raj R, White ES, Palmer SM. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Aug 24;24(1):209. doi: 10.1186/s12931-023-02503-5.
- Ruan P, Todd JL, Zhao H, Liu Y, Vinisko R, Soellner JF, Schmid R, Kaner RJ, Luckhardt TR, Neely ML, Noth I, Porteous M, Raj R, Safdar Z, Strek ME, Hesslinger C, Palmer SM, Leonard TB, Salisbury ML. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31;24(1):141. doi: 10.1186/s12931-023-02435-0.
- Menon AA, Gansen B, Mulder H, Neely ML, Papavasileiou P, Salisbury ML, Southern BD, Hesslinger C, Leonard TB, Meissner F, Todd JL. Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis. Respir Res. 2025 Oct 22;26(1):294. doi: 10.1186/s12931-025-03377-5.
- Shetty S, Swaminathan AC, Li P, Neely ML, Olson AL, Snyder LD; ILD-PRO Registry investigators. Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry. Lung. 2026 May 27;204(1):32. doi: 10.1007/s00408-026-00895-x.
- Swaminathan AC, Mulder H, Neely ML, Schmid R, Belperio JA, Patel NM, Palmer SM, Todd JL. Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis. Respir Res. 2026 Mar 25;27(1):196. doi: 10.1186/s12931-026-03641-2.
- Neely ML, Todd JL, Snyder LD, Li P, Olson AL; IPF-PRO Registry Investigators *. Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. CHEST Pulm. 2024 Dec 27;3(4):100133. doi: 10.1016/j.chpulm.2024.100133. eCollection 2025 Dec.
- MacMurdo MG, Wojdyla DM, Gassett A, Kaufman JD, Raghu G, Redlich CA, Patel DC, Neely ML, Snyder LD, Gulati M, Sack C; IPF-PRO Registry investigators. Short-term air pollution exposure and hospitalizations in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Ann Am Thorac Soc. 2026 Sep 12:aaoag285. doi: 10.1093/annalsats/aaoag285. Online ahead of print.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。